Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ABI-6250

Small molecule · developed by Assembly Biosciences

Phase 2 Most advanced trial

ASMB Developer

1 Registered trials

What is ABI-6250?

ABI-6250 is an oral once-daily tablet studied in chronic hepatitis D infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Infectious disease
Developer: Assembly Biosciences (ASMB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07762027	Phase 2	Chronic Hepatitis D Infection	Not yet recruiting	ASMB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis D Infection

More from Assembly Biosciences

ABI-1179 Phase 1 ABI-4334 Phase 1 ABI-5366 Phase 1 ABI-H2158 Phase 2 ABI-H3733 Phase 1 ABI-M201 Phase 1 Peg-IFNα Phase 2 Vebicorvir Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ASMB page.

Follow ASMB, the company behind ABI-6250

See ASMB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ASMB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z